BioAge Labs (BIOA) Competitors

BioAge Labs logo
$5.22 -0.33 (-5.95%)
Closing price 04:00 PM Eastern
Extended Trading
$5.20 -0.02 (-0.38%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BIOA vs. HROW, IVA, TBPH, COLL, and HELP

Should you buy BioAge Labs stock or one of its competitors? BioAge Labs's main competitors and comparable companies include Harrow (HROW), Inventiva (IVA), Theravance Biopharma (TBPH), Collegium Pharmaceutical (COLL), and Cybin (HELP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BioAge Labs compare to Harrow?

Harrow (NASDAQ:HROW) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Harrow has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Harrow has higher revenue and earnings than BioAge Labs. Harrow is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harrow$272.30M4.01-$5.14M-$0.78N/A
BioAge Labs$8.99M26.69-$80.61M-$2.55N/A

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 17.6% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Harrow has a net margin of -9.39% compared to BioAge Labs' net margin of -1,253.60%. BioAge Labs' return on equity of -31.42% beat Harrow's return on equity.

Company Net Margins Return on Equity Return on Assets
Harrow-9.39% -69.81% -5.16%
BioAge Labs -1,253.60%-31.42%-29.59%

Harrow presently has a consensus target price of $66.20, indicating a potential upside of 127.57%. BioAge Labs has a consensus target price of $33.00, indicating a potential upside of 532.18%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Harrow.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

In the previous week, Harrow had 25 more articles in the media than BioAge Labs. MarketBeat recorded 29 mentions for Harrow and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.48 beat Harrow's score of 0.37 indicating that BioAge Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harrow
5 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Harrow and BioAge Labs tied by winning 7 of the 14 factors compared between the two stocks.

How does BioAge Labs compare to Inventiva?

Inventiva (NASDAQ:IVA) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Inventiva has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

BioAge Labs has higher revenue and earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inventiva$5.07M156.37-$400.67MN/AN/A
BioAge Labs$8.99M26.69-$80.61M-$2.55N/A

19.1% of Inventiva shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 17.6% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inventiva has a net margin of 0.00% compared to BioAge Labs' net margin of -1,253.60%. Inventiva's return on equity of 0.00% beat BioAge Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
InventivaN/A N/A N/A
BioAge Labs -1,253.60%-31.42%-29.59%

Inventiva presently has a consensus price target of $14.67, suggesting a potential upside of 342.43%. BioAge Labs has a consensus price target of $33.00, suggesting a potential upside of 532.18%. Given BioAge Labs' higher possible upside, analysts plainly believe BioAge Labs is more favorable than Inventiva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inventiva
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

In the previous week, BioAge Labs had 1 more articles in the media than Inventiva. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Inventiva. Inventiva's average media sentiment score of 0.57 beat BioAge Labs' score of 0.48 indicating that Inventiva is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inventiva
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Inventiva beats BioAge Labs on 10 of the 15 factors compared between the two stocks.

How does BioAge Labs compare to Theravance Biopharma?

BioAge Labs (NASDAQ:BIOA) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Theravance Biopharma has a net margin of 51.58% compared to BioAge Labs' net margin of -1,253.60%. Theravance Biopharma's return on equity of -0.77% beat BioAge Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
BioAge Labs-1,253.60% -31.42% -29.59%
Theravance Biopharma 51.58%-0.77%-0.46%

BioAge Labs has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

99.1% of Theravance Biopharma shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Theravance Biopharma has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAge Labs$8.99M26.69-$80.61M-$2.55N/A
Theravance Biopharma$104.31M8.48$105.89M$1.0116.86

In the previous week, BioAge Labs had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for BioAge Labs and 2 mentions for Theravance Biopharma. BioAge Labs' average media sentiment score of 0.48 beat Theravance Biopharma's score of 0.36 indicating that BioAge Labs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Theravance Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioAge Labs presently has a consensus price target of $33.00, indicating a potential upside of 532.18%. Theravance Biopharma has a consensus price target of $19.00, indicating a potential upside of 11.57%. Given BioAge Labs' stronger consensus rating and higher possible upside, research analysts plainly believe BioAge Labs is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Theravance Biopharma
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

BioAge Labs and Theravance Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Collegium Pharmaceutical?

BioAge Labs (NASDAQ:BIOA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Collegium Pharmaceutical has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAge Labs$8.99M26.69-$80.61M-$2.55N/A
Collegium Pharmaceutical$780.57M1.01$62.87M$1.0025.43

BioAge Labs has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than BioAge Labs. MarketBeat recorded 8 mentions for Collegium Pharmaceutical and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.48 beat Collegium Pharmaceutical's score of 0.07 indicating that BioAge Labs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Collegium Pharmaceutical
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioAge Labs presently has a consensus price target of $33.00, indicating a potential upside of 532.18%. Collegium Pharmaceutical has a consensus price target of $44.00, indicating a potential upside of 73.02%. Given BioAge Labs' higher probable upside, equities analysts clearly believe BioAge Labs is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Collegium Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90

Collegium Pharmaceutical has a net margin of 4.68% compared to BioAge Labs' net margin of -1,253.60%. Collegium Pharmaceutical's return on equity of 85.14% beat BioAge Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
BioAge Labs-1,253.60% -31.42% -29.59%
Collegium Pharmaceutical 4.68%85.14%13.80%

Summary

Collegium Pharmaceutical beats BioAge Labs on 11 of the 15 factors compared between the two stocks.

How does BioAge Labs compare to Cybin?

BioAge Labs (NASDAQ:BIOA) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

BioAge Labs has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Cybin has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

BioAge Labs presently has a consensus target price of $33.00, indicating a potential upside of 532.18%. Cybin has a consensus target price of $47.33, indicating a potential upside of 517.12%. Given BioAge Labs' higher possible upside, equities analysts plainly believe BioAge Labs is more favorable than Cybin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Cybin
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

BioAge Labs has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAge Labs$8.99M26.69-$80.61M-$2.55N/A
CybinN/AN/A-$148M-$3.02N/A

In the previous week, Cybin had 7 more articles in the media than BioAge Labs. MarketBeat recorded 11 mentions for Cybin and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.48 beat Cybin's score of 0.11 indicating that BioAge Labs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cybin
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

17.9% of Cybin shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cybin has a net margin of 0.00% compared to BioAge Labs' net margin of -1,253.60%. BioAge Labs' return on equity of -31.42% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
BioAge Labs-1,253.60% -31.42% -29.59%
Cybin N/A -71.78%-64.81%

Summary

BioAge Labs beats Cybin on 10 of the 14 factors compared between the two stocks.

Get BioAge Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOA vs. The Competition

MetricBioAge LabsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$259.67M$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E Ratio-2.0526.0432.9127.37
Price / Sales26.697.318.595.73
Price / CashN/A15.7421.9322.50
Price / Book0.695.144.403.70
Net Income-$80.61M$2.88B$3.52B$392.17M
7 Day Performance-8.26%-3.87%-5.34%-4.53%
1 Month Performance7.85%-3.96%-3.61%-5.86%
1 Year Performance-33.08%-7.13%0.01%-7.78%

BioAge Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIOA
BioAge Labs
2.9023 of 5 stars
$5.22
-5.9%
$33.00
+532.2%
-28.8%$259.67M$8.99MN/A62
HROW
Harrow
2.8655 of 5 stars
$27.49
+2.2%
$66.17
+140.7%
-26.2%$1.03B$272.30MN/A373
IVA
Inventiva
2.6693 of 5 stars
$3.85
+1.2%
$14.67
+281.4%
-8.0%$915.06M$49KN/A77
TBPH
Theravance Biopharma
1.5483 of 5 stars
$17.03
flat
$19.00
+11.6%
N/A$884.18M$104.31M16.86110
COLL
Collegium Pharmaceutical
3.7933 of 5 stars
$24.68
+1.9%
$44.88
+81.8%
-44.9%$803.74M$780.57M24.69423

Related Companies and Tools


This page (NASDAQ:BIOA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners